Investments, Funding & Disinvestment

President Donald Trump initiated this process exactly one year ago when he signed an executive order on his first day in office in 2025, pointing to what he described as the organization’s “mishandling of the COVID-19 pandemic” and its response to “other global health crises.”

The company plans to use the funding primarily to support a phase 2 clinical study evaluating Deraphan, its experimental treatment for agitation in patients with Alzheimer’s disease.

Insilico will lead the initial phase, advancing ISM8969 through preclinical studies and into a phase 1 clinical trial for Parkinson’s disease.

The deal centers on ozureprubart, an anti-immunoglobulin E (IgE) antibody that could transform how patients manage life-threatening food allergies.

The transaction marks the end of Pfizer’s involvement with ViiV Healthcare, as the American pharmaceutical giant sells its entire 11.7% stake in the company.

AbelZeta will receive up to USD630 million from AstraZeneca, with the payment structure including both upfront cash and milestone fees tied to the GPC3 program’s progress in China.

The company recently filed a New Drug Application (NDA) with the U.S. Food and Drug Administration for its first BFS-based prefilled injection device, achieving a major regulatory breakthrough for the platform.

The company plans to develop the first phase of this facility on a 10,000 square metre site with an initial investment of RO 15 million (USD39 million).

Penumbra shareholders will have the option to receive either USD374 in cash or 3.8721 Boston Scientific shares, with the transaction structured as approximately 73% cash and 27% stock.

The company plans to bring Neopak Glass Prefillable Syringe production to its long-established facility in Columbus, Nebraska.